Intellia Therapeutics (NTLA) Non Operating Investment Income (2019 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Non Operating Investment Income of -$1.3 million for Q1 2026, down 381.42% year-over-year from $452000.0 in Q1 2025, and down 230.39% quarter-over-quarter from -$385000.0 in Q4 2025.
Powered by 
Analysis
Intellia Therapeutics (NTLA) Non Operating Investment Income (2019 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Non Operating Investment Income for 7 consecutive years, with -$1.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Investment Income fell 381.42% year-over-year to -$1.3 million; the TTM figure through Mar 2026 stood at $3.1 million (down 56.94% YoY), while the FY2024 annual figure was $731000.0, changed N/A from the prior year.
- Non Operating Investment Income fell to -$1.3 million in Q1 2026 per NTLA's latest filing, from -$385000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $30.2 million in Q4 2024 and bottomed at -$20.4 million in Q2 2024.
- Historically, Non Operating Investment Income has averaged $331076.9 across 4 years, with a median of -$385000.0 in 2025.
- On a YoY basis, Non Operating Investment Income climbed as much as 715.53% in 2022 and fell as far as 93100.0% in 2022.
- Intellia Therapeutics' Non Operating Investment Income stood at $5.1 million in 2022, then jumped by 496.05% to $30.2 million in 2024, then plunged by 101.27% to -$385000.0 in 2025, then tumbled by 230.39% to -$1.3 million in 2026.
- Business Quant data shows NTLA's Non Operating Investment Income at -$1.3 million in Q1 2026, -$385000.0 in Q4 2025, and $3.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Intellia Therapeutics | 1.70 Bn | 1.70 Bn | - | -790,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -790,000.00 |
| Mar 31, 2026 | -1.27 Mn |
| Dec 31, 2025 | -2.65 Mn |
| Sep 30, 2025 | 3.44 Mn |
| Jun 30, 2025 | 1.34 Mn |
| Mar 31, 2025 | -2.13 Mn |
| Dec 31, 2024 | -3.08 Mn |
| Sep 30, 2024 | 4.45 Mn |
| Jun 30, 2024 | -20.35 Mn |
| Mar 31, 2024 | -6.07 Mn |
| Dec 31, 2023 | 1.99 Mn |
| Sep 30, 2023 | 142,000.00 |
| Jun 30, 2023 | -1.48 Mn |
| Mar 31, 2023 | 2.99 Mn |
| Dec 31, 2022 | 3.43 Mn |
| Sep 30, 2022 | 991,000.00 |
| Jun 30, 2022 | -932,000.00 |
| Mar 31, 2022 | -5.13 Mn |
| Dec 31, 2021 | -1.95 Mn |
| Sep 30, 2021 | -161,000.00 |